Movalis (Meloxicam)

Meloxicam blocks the activity of cyclooxygenase enzymes COX‑1 and COX‑2, with a preference for COX‑2. By reducing prostaglandin production, it diminishes the inflammatory response, leading to decreased pain, swelling, and fever in affected tissues.

The exact dose of Movalis is determined by the prescribing clinician based on the specific indication, severity of symptoms, and individual patient factors such as age, weight, and renal function. Dosage recommendations are provided in the product label, but the prescriber sets the final regimen.

Safety data for meloxicam in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Movalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher degree of COX‑2 selectivity, which may reduce gastrointestinal irritation while still providing effective analgesia. However, it shares similar cardiovascular and renal risk profiles, so patient selection and monitoring remain essential.

Movalis should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Movalis is given as an intramuscular injection, typically into the gluteal or deltoid muscle. The injection should be performed by a qualified healthcare professional using aseptic technique, and the dose is administered according to the prescriber’s instructions.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, acute renal failure, severe skin reactions (e.g., Stevens‑Johnson syndrome), hepatic injury, and anaphylaxis. Patients should be educated to seek immediate medical attention if any of these occur.

Movalis is contraindicated in individuals with known hypersensitivity to meloxicam or other oxicam NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and patients who have had a recent coronary artery bypass graft. Caution is also advised for patients with impaired renal or hepatic function.